Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors.
A study led by Maria Carmo-Fonseca at GIMM has helped clarify one of the main limitations of lab-grown heart cells, which are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback